Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Gilead Sciences, Inc. (GILD), featuring income statements, balance sheets, and cash flow data.
Gilead Sciences, Inc. (GILD) Income Statement & Financial Overview
View the income breakdown for Gilead Sciences, Inc. GILD across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $6.67B | $7.57B | $7.54B | $6.95B |
| Cost of Revenue | $1.54B | $1.58B | $1.57B | $1.54B |
| Gross Profit | $5.13B | $5.99B | $5.97B | $5.41B |
| Gross Profit Ratio | $0.77 | $0.79 | $0.79 | $0.78 |
| R&D Expenses | $1.38B | $1.64B | $1.40B | $1.35B |
| SG&A Expenses | $1.26B | $1.91B | $1.43B | $1.38B |
| Operating Expenses | $2.89B | $3.54B | $5.08B | $2.77B |
| Total Costs & Expenses | $4.43B | $5.12B | $6.66B | $4.31B |
| Interest Income | $94.00M | $85.00M | $52.00M | $0.00 |
| Interest Expense | $260.00M | $249.00M | $238.00M | $237.00M |
| Depreciation & Amortization | $696.00M | $693.00M | $690.00M | $694.00M |
| EBITDA | $2.60B | $3.11B | $1.88B | $2.98B |
| EBITDA Ratio | $0.39 | $0.41 | $0.25 | $0.43 |
| Operating Income | $2.24B | $2.45B | $888.00M | $2.64B |
| Operating Income Ratio | $0.34 | $0.32 | $0.12 | $0.38 |
| Other Income/Expenses (Net) | -$588.00M | -$285.00M | $68.00M | -$591.00M |
| Income Before Tax | $1.65B | $2.17B | $956.00M | $2.05B |
| Income Before Tax Ratio | $0.25 | $0.29 | $0.13 | $0.30 |
| Income Tax Expense | $334.00M | $385.00M | -$297.00M | $438.00M |
| Net Income | $1.31B | $1.78B | $1.25B | $1.61B |
| Net Income Ratio | $0.20 | $0.24 | $0.17 | $0.23 |
| EPS | $1.06 | $1.43 | $1.00 | $1.29 |
| Diluted EPS | $1.04 | $1.42 | $1.00 | $1.29 |
| Weighted Avg Shares Outstanding | $1.25B | $1.25B | $1.25B | $1.25B |
| Weighted Avg Shares Outstanding (Diluted) | $1.26B | $1.26B | $1.25B | $1.25B |
Financial performance has remained strong, with revenue growing from $6.95B in Q2 2024 to $6.67B in Q1 2025. Gross profit continued to perform well, with margins at 77% in the latest quarter. Operating income reached $2.24B in Q1 2025, holding a steady 34% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $2.60B. Net income dropped to $1.31B, keeping EPS at $1.06. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan